Journal article
Usability of mepolizumab single-use prefilled autoinjector for patient self-administration
- Abstract:
-
Objective: To evaluate usability of mepolizumab as a liquid drug product self-administered via a single-use prefilled autoinjector (AI) by patients with severe eosinophilic asthma (SEA), or their caregivers, in-clinic and at home.
Methods: This open-label, single-arm, Phase IIIa study (NCT03099096; GSK ID: 204959) included patients aged ≥12 years with SEA who were either receiving mepolizumab (100 mg subcutaneously [SC]) every 4 weeks (Q4W) for ≥12... Expand abstract
- Publication status:
- Published
- Peer review status:
- Peer reviewed
Actions
Authors
Bibliographic Details
- Publisher:
- Taylor and Francis Publisher's website
- Journal:
- Journal of Asthma Journal website
- Volume:
- 57
- Issue:
- 9
- Pages:
- 987-998
- Publication date:
- 2019-06-28
- Acceptance date:
- 2019-06-07
- DOI:
- EISSN:
-
1532-4303
- ISSN:
-
0277-0903
- Pmid:
-
31251090
Item Description
- Language:
- English
- Keywords:
- Pubs id:
-
pubs:1028524
- UUID:
-
uuid:d0be99f5-8254-4e6a-851b-2b5d1f78fea1
- Local pid:
- pubs:1028524
- Source identifiers:
-
1028524
- Deposit date:
- 2019-08-01
Terms of use
- Copyright holder:
- GlaxoSmithKline
- Copyright date:
- 2019
- Rights statement:
- © 2019 GlaxoSmithKline. Published with license by Taylor & Francis Group, LLC. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/Licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
- Licence:
- CC Attribution (CC BY)
Metrics
If you are the owner of this record, you can report an update to it here: Report update to this record